Presentation on theme: "The Role of Bioavailability in Pharmaceutical Product Development Alwyn Pidgen Pharmacokinetics consultant."— Presentation transcript:
1The Role of Bioavailability in Pharmaceutical Product Development Alwyn Pidgen Pharmacokinetics consultant
2Formulations include:- Tablet, Suspension, Capsule, Solution, Powder Different routes & formulations can impact the speed and completeness of drug absorptionINTRAVASCULAR IntravenousEXTRAVASCULAR Intra-muscular; Subcutaneous; Oral; Rectal; Topical; Inhalation; Intranasal; Transdermal; Sublingual; BuccalFormulations include:-Tablet, Suspension, Capsule, Solution, PowderAerosol, Nebulizer, Dry Powder Inhaler (DPI)Lotion, Ointment, CreamSuppository, Rectal solution, Implants
3Absolute Bioavailability Absolute bioavailability - Is the proportion of intact drug, which reaches the systemic circulation following extravascular administration when compared to an intravenous dose.CivoralTimeF(abs) = AUC(oral) * Dose(iv)AUC(iv) Dose(oral)
4Relative Bioavailability Relative bioavailability - Is the bioavailability of one dosage form (e.g. tablet) relative to another (e.g. capsule) - or one route of administration (e.g. rectal) relative to another (e.g. oral).CoralrectalTimeF(rel) = AUC(rectal) * Dose(oral)AUC(oral) Dose(rectal)
5BioequivalenceTwo medicinal products can be classed as bioequivalent when their rate and extent of absorption meet strict regulatory requirements after administration of the same molar dose.
6Pharmaceutical equivalence Medicinal products are called Pharmaceutical equivalents if they contain the same amount of the same active substance in the same dosage form, which meet the same or comparable standards.
7HOWEVER - Pharmaceutical equivalence does not automatically assure bioequivalence mainly due to changes in dissolution, which can be influenced by: -Particle sizePhysico-chemical factors of drugSolubilityUse of different excipientsDegree of agitationChange in manufacturing processFood
8Particle sizeIn general, the smaller the particle size the faster the absorption. The analgesic phenacetin (shown below) was tested in various suspension dosage forms.
9KEY CONCEPT IN BIOEQUIVALENCE ‘Equal amounts of the same drug administered in different products will show equal therapeutic effects’.A direct demonstration of therapeutic equivalence requires a clinical trial HOWEVERThis is replaced by the indirect approach of a bioequivalence trial based on the principle that:-‘Two medicinal products that give rise to ‘essentially equivalent’ concentrations of the active species in blood (viewed as a profile over time) will give equivalent therapeutic effects’.
10Why perform Bioequivalence studies ? To enable clinical trial formulations to be modified or production ‘scaled up’ throughout a drug’s development.To compare a clinical trial formulation with the ‘to be marketed’ product just prior to filing.To compare a generic drug product with a corresponding reference drug.To change the dosage regimen by means of a change in formulationImmediate release Modified-release
11When are bioequivalence studies not normally needed ? If the product differs only in the strength of the active substance it contains and the pharmacokinetics are linearIf the product has been slightly reformulated or the manufacturing method slightly modified by the original manufacturer in ways that can be argued to be irrelevant (using in-vitro tests)If the product is to be administered parenterally as a solution and contains the same active substances and excipients as a medicinal product currently approved.
12If the product is a liquid oral form in solution containing the active substance in the same concentration and form as a currently approved medicinal productAn acceptable correlation between dissolution rate in-vivo and in-vitro has been shown (FDA guidance).Products intended for local use to act without systemic absorption
13F1 = Tablet (kit) F2 = Tablet (co-precipitate) F3 = Softgel FDA Criteria met for F2 Tablet (co-precipitate) & F1 Tablet (Kit) but not for F3 (Softgel).
14Typical Study Design Features Healthy volunteersMale subjects or women of non-child bearing potentialAged between 18 and 55Single dose.Crossover design – first choiceParallel group design - for drugs with long half-livesReplicate design - for highly variable drugs
15SAMPLE SIZEShould be appropriately statistically powered if study is pivotal for filingAn estimate of a drug’s intrinsic variability is obtained from previous studies or publicationsShould not be smaller than 12
16What to measureFor BE studies - measurement of plasma concentrations of the parent drug are recommended.Parent drug is more sensitive to formulation changes than any metabolite.For an inactive pro-drug the main active metabolite should be measured if the plasma levels of the parent are too low for accurate assay measurement.Examples of prodrugsEnalapril (hypertension) is metabolised to the active form EnalaprilatValacyclovir (herpes virus) is metabolised to the active form Acyclovir
17Enantiomers versus Racemates For BE studies measurement of the racemate is recommended.Measurement of individual enantiomers is recommended if:-The enantiomers have different PK or PD characteristicsThe exposure (AUC ratio) of the enantiomers is modified by a difference in the rate of absorption.If one enantiomer is pharmacologically active and the other contributes little to activity, it is sufficient to demonstrate bioequivalence for the active enantiomer only.
18Fixed combinationsA separate BE analysis should be performed on each active substance in a fixed combination. This is achieved by considering all other active substances (in turn) as excipients.Endogenous substancesDifficult area. A pilot study may be useful to check the effect. Baseline correction of background levels are required to ensure that drug levels reflect the treatments under test. A longer washout period may be required.
19PHARMACOKINETIC PARAMETERS Early exposureOnly consider if making a claim for clinically relevant rapid release - and/or - if onset of action is related to adverse events.Rapid onset of analgesic effectAvoidance of excessive hypotensive actionParameters include AUC(0–tmax) (FDA) and tmax (EMEA)Peak exposureImportant parameter - may have potential links to safety and/or efficacy.Parameter is Maximum observed drug concentration (Cmax)
20Total exposureThis is the most important BE parameter since AUC is directly proportional to the amount of drug absorbed.ParametersAUC to the last measurable time point (AUC0-t)AUC truncated at 72h (AUC0-72) – (EMEA only)AUC extrapolated to infinite time (AUC0-inf)The elimination rate constant (kel) and terminal half-life (t1/2) should be reported - particularly if AUC(0-inf) is used.
21STATISTICAL ANALYSISCalculate 90% confidence intervals of the ratio of the treatment means (test/reference) for Cmax, and AUC.The data are log transformed prior to analysis.If statistical evaluation of tmax is required then a non-parametric hypothesis test is performed on the untransformed data.
22Bioequivalence region For Bioequivalence - the ratio of the geometric means µT/µR of the test and reference products must be ≥ 0.8 and ≤ 1.25.BioequivalenceregionµT/µR0.81.25Bio-inequivalenceregionBio-inequivalenceregion
23The Regulatory acceptance criteria AUC : test treatment to be within ≥ 0.8 and ≤ 1.25 of the reference treatment (FDA and EMEA)Range to be tightened in the case of a drug with a narrow therapeutic window (e.g. digoxin, phenytoin) (FDA and EMEA). This may also be applicable to Cmax.Cmax : test treatment to be within ≥ 0.8 and ≤ 1.25 of the reference treatment (FDA and EMEA)A wider interval may be acceptable (EMEA only). The actual limits vary according to the within-subject variability (%CV) noted in the bioequivalence study. See EMEA guidelines for details.tmax : Only consider if clinically relevant rapid release is claimed and/or onset of action is related to adverse events.
24An example Propafenone – anti-arrhythmic drug Undergoes extensive first-pass metabolismVariable half-lifeBioequivalence study undertakenApotex (Reference) v Rhythmol (Test)300mg tablet18 healthy subjects2-way crossover‘Highly Variable Drugs:Experience with Propafenone’ -Yu Chung Tsang, Radu Pop & Michael Spino
28Reasons for BE failure Very high inter-subject CV for Cmax & AUC High overall intra-subject variability (46%)Variability in elimination characteristicsThe metabolism of propafenone is influenced by geneticst1/2 (fast metabolisers) = 2-10ht1/2 (slow metabolisers) = 10-32hDrug levels 5 times higher in slow metabolisers
29Biogenerics – current status Hot topic – large market potential – lot of issuesMore regulatory obstacles than with traditional ‘small molecule’ generics.FDA position still under reviewEMEA guidance availableNumerous position papersCurrent ANDA approach not considered scientifically appropriate for biotechnology productsCompanies asked to show ‘biosimilarity’ – this involves clinical trials to demonstrate safety/efficacy
30Biogenerics – why the problems ? Protein products have a greater structural complexity, often difficult to characterize and have a much higher molecular weight than ‘small molecule drugs’.They can be mixtures of many molecular species and can have unique impurity profiles that depend upon the manufacturing process.
31Biogenerics - manufacture Small changes in the manufacturing process can lead to big changes in the drugs safety & efficacy. FDA collecting examples to evaluate this claim.Improvements in protein technology mean manufacturers can no longer produce a protein that would have identical characteristics to the original.Implications - altered PK & PD of the protein - ultimately leading to clinical implications.
32Useful Regulatory Guidance documents FDA (www.fda.gov/cder/guidance/index.htm)Bioavailability & Bioequivalence studies for orally administered drug products – general considerations – March 2003Food-effect Bioavailability & Fed Bioequivalence studies – December 2002Modified Release Solid Oral Dosage Forms - Scale-Up and Post-approval Changes: Chemistry, Manufacturing and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation – Sept 1997Dissolution testing of Immediate release solid oral dosage forms - Aug 97Extended release oral dosage forms : Development, Evaluation & Application of In-vitro/In-vivo correlations – Sept 97EMEA (www.emea.europa.eu/index/indexh1.htm)Guideline on the Investigation of Bioequivalence - January Doc. Ref.CPMP/EWP/QWP/1401/98Guideline on Similar Biological Medicinal products – November 2004Note for guidance on quality of Modified Release products (A Oral dosage forms; B Transdermal dosage forms) – July 1999Guideline on Similar Biological Medicinal Products – Nov 2004Guideline on Similar Biological Medicinal Products containing Biotechnology-derived Proteins as active substance: Quality Issues – June 2005